Breaking News, Collaborations & Alliances, Trials & Filings

Quintiles To Manage Blepharitis Trial

InSite Vision Selects CRO for DOUBle Trial

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

InSite Vision has selected Quintiles to manage the DOUBle Phase III trial of AzaSite Plus and DexaSite for the treatment of blepharitis. In May 2011, InSite Vision obtained a Special Protocol Assessment (SPA) from the FDA for the DOUBle Trial. AzaSite Plus and DexaSite are formulated with the company’s proprietary DuraSite drug delivery platform: AzaSite Plus combines dexamethasone 0.1% with the antibiotic AzaSite (azithromycin 1% ophthalmic solution) in DuraSite and DexaSite combines dexametha...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters